First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

被引：2

作者：

Braulke, Friederike ^{[1
,2
]}

Zettl, Florian ^{[3
]}

Ziepert, Marita ^{[4
]}

Viardot, Andreas ^{[5
]}

Kahl, Christoph ^{[6
,7
]}

Prange-Krex, Gabriele ^{[8
]}

Korfel, Agnieszka ^{[9
,10
]}

Dreyling, Martin ^{[11
]}

Bott, Alexander ^{[12
]}

Wedding, Ulrich ^{[13
]}

Reichert, Dietmar ^{[14
]}

de Wit, Maike ^{[15
]}

Hartmann, Frank ^{[16
]}

Poeschel, Viola ^{[17
]}

Schmitz, Norbert ^{[18
]}

Witzens-Harig, Mathias ^{[19
]}

Klapper, Wolfram ^{[20
,21
]}

Rosenwald, Andreas ^{[22
]}

Wulf, Gerald ^{[1
,2
]}

Altmann, Bettina ^{[4
]}

Trumper, Lorenz ^{[1
,2
]}

机构：

[1] Univ Med Ctr Goettingen, Dept Hematol & Med Oncol, Gottingen, Germany

[2] Univ Med Ctr Goettingen, Comprehens Canc Ctr, Gottingen, Germany

[3] Klinikum Traunstein, Dept Hematol & Oncol, Traunstein, Germany

[4] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Leipzig, Germany

[5] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[6] Klinikum Magdeburg, Dept Hematol Oncol & Palliat Care, Magdeburg, Germany

[7] Rostock Univ, Dept Internal Med Clin Hematol Oncol & Palliat Ca, Med Ctr, Rostock, Germany

[8] Onkol Gemeinschaftspraxis, Dresden, Germany

[9] Charite, Dept Hematol & Oncol, Berlin, Germany

[10] Lilly GmbH, Med Dept Oncol, Bad Homburg, Germany

[11] Univ Hosp Ludwig Maximilians Univ, Dept Med 3, Munich, Germany

[12] Paracelsus Med Univ, Dept Hematol & Med Oncol, Nuermberg, Germany

[13] Jena Univ Hosp, Dept Palliat Care, Jena, Germany

[14] Outpatient Ctr Oncol, Westerstede, Germany

[15] Vivantes Klinikum Neukolln, Klin Innere Med Hamatol Onkol & Palliat Med, Berlin, Germany

[16] Klinikum Lippe, Dept Hematol & Oncol, Lemgo, Germany

[17] Saarland Univ, Med Oncol Hematol Clin Immunol & Rheumatol 1, Med Sch, Homburg, Germany

[18] Univ Med Muenster, Med Dept A, Hematol & Oncol, Munster, Germany

[19] Univ Hosp Heidelberg, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[20] Univ Hosp Schleswig Holstein, Dept Pathol, Hematopathol Sect, Kiel, Germany

[21] Univ Hosp Schleswig Holstein, Lymph Node Registry Kiel, Kiel, Germany

[22] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany

来源：

HEMASPHERE | 2022年 / 6卷 / 12期

关键词：

NON-HODGKIN-LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL; CELL LYMPHOMA; ELDERLY-PATIENTS; PHASE-II; PLUS BENDAMUSTINE; SINGLE-ARM; COMBINATION; MULTICENTER; ILLNESS;

D O I：

10.1097/HS9.0000000000000808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option.

引用

页数：10